CIBC Private Wealth Group
AKBA icon

CIBC Private Wealth Group’s Akebia Therapeutics AKBA Stock Holding History

CIBC Private Wealth Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,825
Closed -$3.73K – 2974
2024
Q3 		$3.73K Buy
2,825
+2,725
+2,725% +$3.64K ﹤0.01% 2679
2024
Q2 		$95 Hold
100
– – ﹤0.01% 3093
2024
Q1 		$163 Buy
+100
New +$160 ﹤0.01% 3000

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CIBC Private Wealth Group's AKBA Position: Q4 2024 in Review

CIBC Private Wealth Group sold out of Akebia Therapeutics (AKBA) in Q4 2024, closing a stake of 2,825 shares — an estimated $3.73K sold.

CIBC Private Wealth Group first reported a position in AKBA in Q1 2024 and held it in 3 quarters. The position peaked at $3.73K in Q3 2024. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • CIBC Private Wealth Group reported no remaining Akebia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CIBC Private Wealth Group sold 2,825 Akebia Therapeutics shares in Q4 2024, an estimated $3.73K.
  • CIBC Private Wealth Group first reported a position in Akebia Therapeutics in Q1 2024 and held it in 3 quarters.
  • CIBC Private Wealth Group's Akebia Therapeutics position peaked at $3.73K in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on CIBC Private Wealth Group's 13F filing for Q4 2024, filed 12 Feb 2025.